Donanemab – A GP guide to anti-amyloid therapies

In this Healthed lecture, Professor Henry Brodaty explains the evidence for the effectiveness of Donanemab in slowing cognitive and functional decline, with the greatest benefit being seen in early-stage patients. In addition, he will discuss the practical aspects of the treatment including patient selection, assessment, referral process as well as how the monthly IV infusions are delivered, monitored, and potential side effects. Professor Brodaty will also address the reality that the effectiveness of donanemab is not universal and careful patient selection and managing expectations is important.

See omnystudio.com/listener for privacy information.